ZLAB Earnings Date: Nov 5, 2026 (Estimated) — Zai Lab Limited
NASDAQ · Healthcare · Biotechnology
Updated
When is ZLAB's next earnings date?
Zai Lab Limited (ZLAB) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.56 on revenue of $108.8M.
How did ZLAB do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Zai Lab Limited posted EPS of -$0.46 versus the -$0.68 estimate, a beat of 29.2%. Revenue was $105.8M against a $103.9M estimate. The stock's 1-day post-earnings move was +13.7%.
How much does ZLAB stock move after earnings?
ZLAB beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.1% (up or down) in the day after earnings.
About Zai Lab Limited
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.68 | -0.46 | +29.23% | $105.8M | ✅ Beat | +13.66% | +38.76% | +46.98% |
| 2026-05-07 | Q1 2026 | -0.54 | -0.46 | +14.81% | $99.6M | ✅ Beat | -5.93% | -2.57% | -20.89% |
| 2026-02-26 | Q4 2025 | -0.43 | -0.46 | -6.98% | $127.6M | ❌ Miss | +1.55% | -0.62% | -9.70% |
| 2025-11-06 | Q3 2025 | -0.29 | -0.33 | -13.79% | $116.1M | ❌ Miss | -6.65% | -11.77% | -21.37% |
| 2025-08-07 | Q2 2025 | -0.40 | -0.37 | +7.50% | $110.0M | ✅ Beat | -11.98% | -7.98% | -20.45% |
| 2025-02-27 | Q4 2024 | -0.07 | -0.80 | -1042.86% | $109.1M | ❌ Miss | -1.97% | +2.40% | +3.17% |
| 2024-11-12 | Q3 2024 | -0.78 | -0.42 | +46.15% | $102.3M | ✅ Beat | -6.85% | -19.04% | -12.64% |
| 2024-08-06 | Q2 2024 | -0.70 | -0.82 | -17.14% | $100.5M | ❌ Miss | -8.06% | -10.27% | +8.45% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $71.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Zejula | 45.1% | $32.1M | -21.8% | $141.6M | $49.5M | $41.0M | $42.4M |
| Nuzyra | 24.0% | $17.1M | +19.6% | $33.3M | $15.1M | $14.3M | $15.4M |
| Optune | 17.1% | $12.2M | -1.2% | $28.0M | $11.4M | $12.4M | $12.7M |
| Qinlock | 13.5% | $9.6M | +12.3% | $22.7M | $8.5M | $8.5M | $8.9M |
| Product and Service, Other | 0.3% | $195K | -43.0% | — | $283K | $342K | $92K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.